{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:28:30Z","timestamp":1793035710750,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":287,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephrol. Dial. Transplant."],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/ndt\/gfv456","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T20:18:20Z","timestamp":1454185100000},"page":"337-348","source":"Crossref","is-referenced-by-count":224,"title":["Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice"],"prefix":"10.1093","volume":"31","author":[{"given":"Ron T.","family":"Gansevoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Drechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wi\u0119cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,29]]},"reference":[{"key":"2016022507073081000_31.3.337.1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32835011a7"},{"key":"2016022507073081000_31.3.337.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60659-0"},{"key":"2016022507073081000_31.3.337.3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu017"},{"key":"2016022507073081000_31.3.337.4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.120"},{"key":"2016022507073081000_31.3.337.5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070650"},{"key":"2016022507073081000_31.3.337.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0804458"},{"key":"2016022507073081000_31.3.337.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60907-2"},{"key":"2016022507073081000_31.3.337.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.109"},{"key":"2016022507073081000_31.3.337.9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.59"},{"key":"2016022507073081000_31.3.337.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205511"},{"key":"2016022507073081000_31.3.337.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"2016022507073081000_31.3.337.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403313301301"},{"key":"2016022507073081000_31.3.337.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"2016022507073081000_31.3.337.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"2016022507073081000_31.3.337.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6634"},{"key":"2016022507073081000_31.3.337.16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030"},{"key":"2016022507073081000_31.3.337.17","unstructured":"European Medicines Agency. Guideline on the Clinical Investigation of Medicinal Products to Prevent Development\/Slow Progression of Chronic Renal Insufficiency . https:\/\/www.google.nl\/search?q=EMA%2FCHMP%2F355988%2F2014&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:nl:official&client=firefox-a&channel=fflb&gfe_rd=cr&ei=gXF4VqT2JYO--Qan84OADQ (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.18","unstructured":"European Medicines Agency. Public Assessment Report Jinarc . http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002788\/WC500187923.pdf (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.19","unstructured":"Reference to FDA Complete Response Letter 2013 . http:\/\/www.businesswire.com\/news\/home\/20130829006215\/en\/Otsuka-Receives-Complete-Response-Letter-U.S.-Food (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1985.205"},{"key":"2016022507073081000_31.3.337.21","unstructured":"The REPRISE Study. Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02160145 (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.22","unstructured":"National Institute for Health and Care Excellence. Final Appraisal Determination: Tolvaptan for Treating Autosomal Dominant Polycystic Kidney Disease . http:\/\/www.nice.org.uk\/guidance\/TA358\/documents\/kidney-disease-autosomal-dominant-polycystic-tolvaptan-id652-final-appraisal-determination-document2 (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.23","unstructured":"Torres VE , Higashihara E , Devuyst O et al . Effect of tolvaptan in ADPKD by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 2015; accepted for publication"},{"key":"2016022507073081000_31.3.337.24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013111184"},{"key":"2016022507073081000_31.3.337.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0114-5"},{"key":"2016022507073081000_31.3.337.26","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09500911"},{"key":"2016022507073081000_31.3.337.27","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00330705"},{"key":"2016022507073081000_31.3.337.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054341"},{"key":"2016022507073081000_31.3.337.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-012-0611-9"},{"key":"2016022507073081000_31.3.337.30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013101138"},{"key":"2016022507073081000_31.3.337.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114248"},{"key":"2016022507073081000_31.3.337.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032533"},{"key":"2016022507073081000_31.3.337.33","doi-asserted-by":"publisher","DOI":"10.1159\/000256657"},{"key":"2016022507073081000_31.3.337.34","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.03.030"},{"key":"2016022507073081000_31.3.337.35","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"2016022507073081000_31.3.337.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.214"},{"key":"2016022507073081000_31.3.337.37","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.558"},{"key":"2016022507073081000_31.3.337.38","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.017"},{"key":"2016022507073081000_31.3.337.39","unstructured":"Clinical Guidelines for Polycystic Kidney Disease 2014 Advisory Committee. Evidence-Based Clinical Practice Guidelines for Polycystic Kidney Disease 2014. Japan . http:\/\/www.jsn.or.jp\/BCD1572E-0531-492B-BBDD-803B7BF77CE2\/FinalDownload\/DownloadId-BA08C144CD972059AB5B1F6CCB4D1BE5\/BCD1572E-0531-492B-BBDD-803B7BF77CE2\/guideline\/pdf\/PKD_eng.pdf (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.40","unstructured":"Mayo ADPKD Class Calculator . http:\/\/www.mayo.edu\/research\/documents\/pkd-center-adpkd-classification\/doc-20094754 (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.41","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.71"},{"key":"2016022507073081000_31.3.337.42","doi-asserted-by":"crossref","unstructured":"Cornec-Le Gall E , Audr\u00e9zet MP , Rousseau A et al . The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2015; doi:10.1681\/ASN.2015010016 doi:10.1681\/ASN.2015010016","DOI":"10.1681\/ASN.2015010016"},{"key":"2016022507073081000_31.3.337.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.66003.x"},{"key":"2016022507073081000_31.3.337.44","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009020162"},{"key":"2016022507073081000_31.3.337.45","unstructured":"European Medicines Agency. Summary of Medicinal Product Characteristics Jinarc . http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002788\/WC500187921.pdf (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.46","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0327-3"},{"key":"2016022507073081000_31.3.337.47","unstructured":"FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation, 2009 . http:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/UCM174090.pdf (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.48","unstructured":"FDA Briefing Document NDA 204441. Delaying Progression of Renal Complications of ADPKD by Tolvaptan Inhibition of Arginine Vasopressin, 2013 . http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM363345.pdf (10 November 2015, date last accessed)"},{"key":"2016022507073081000_31.3.337.49","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.285"},{"key":"2016022507073081000_31.3.337.50","doi-asserted-by":"publisher","DOI":"10.1042\/bj1360705"},{"key":"2016022507073081000_31.3.337.51","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.119"},{"key":"2016022507073081000_31.3.337.52","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.23"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/31\/3\/337\/7430762\/gfv456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T10:41:37Z","timestamp":1522665697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfv456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,29]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,2,22]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1093\/ndt\/gfv456"],"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfv456","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,29]]}}}